新型的RORγt逆agonists限制IL-17介导的肝炎和纤维化
Afrooz Dabbaghizadeh1,2, Jessica Dion1, Yousef Maali1,2
1Centre de Recherche du Centre Hospitalier de l'Université de Montréal (CRCHUM), Montréal, QC, Canada.
Journal of immunology (Baltimore, Md. : 1950)
|March 12, 2025
概括
新型RORγt逆agonists通过抑制IL-17A的产生和炎症细胞透,有效地减少了小鼠的肝纤维化. 这些发现突显了针对IL-17A途径治疗肝纤维化的治疗潜力.
科学领域:
- 肝病学 肝病学是一种肝病学.
- 免疫学 免疫学 免疫学
- 药理学 药理学 是一个学科.
背景情况:
- 肝纤维化是一个重要的全球健康问题.
- 干白素-17A (IL-17A) 参与促进肝纤维化.
- RORγt是T细胞对IL-17A产生的一个关键调节剂.
研究的目的:
- 在肝纤维化小鼠模型中评估新型RORγt逆agonists的治疗潜力.
- 研究这些激动剂对IL-17A产生和炎症细胞透的影响.
- 评估对肝损伤标志物和纤维化基因表达的影响.
主要方法:
- 在C57BL/6小鼠中的CCl4诱导肝损伤模型.
- 用新型RORγt逆激素激应剂 (TF-S10,TF-S14) 和阳性对照 (GSK805) 进行治疗.
- 对免疫细胞种群,IL-17A水平,肝酶,肝指数,肝星细胞激活标志物,益基因表达和原沉积的分析.
主要成果:
- 反向激动剂减少了免疫细胞透和肝酶 (AST).
- TF-S14显著降低了AST水平,所有抑制剂都改善了肝脏指数.
- 抑制剂降低了肝脏内淋巴细胞,骨髓细胞和IL-17A的产生,导致肝脏星状细胞激活和益菌原基因表达减少,并减少了原沉积.
结论:
- 通过RORγt逆agonists抑制IL-17A通路在肝纤维化小鼠模型中证明了治疗效果.
- 准IL-17A是治疗肝纤维化的有希望的策略.
- 新型RORγt逆agonists显示出作为一种新型肝纤维化治疗药物类别的潜力.
相关概念视频
01:24T Cell Types and Functions
740
When T cells with CD4 markers are activated, they give rise to two types of effector cells: helper T cells and regulatory T cells. Meanwhile, T cells with CD8 markers differentiate into effector cytotoxic T cells. The differentiation of CD4 T cells into helper T cell subsets, such as Th1, Th2, and Th17 cells, is dependent on the antigen type, antigen-presenting cell, and regulatory cytokines.
Th1 cells stimulate dendritic cells to express necessary co-stimulatory molecules on their surfaces for...
Th1 cells stimulate dendritic cells to express necessary co-stimulatory molecules on their surfaces for...
740
01:24Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
107
Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab...
107
01:29Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
126
Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel...
126
01:21Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids
92
Glucocorticoids, a class of anti-inflammatory drugs, are pivotal in treating moderate to severe Crohn's disease by inducing remission. They exhibit their anti-inflammatory action by inhibiting the production of inflammatory cytokines such as tumor necrosis factor (TNF)-α, interleukin (IL)-1, and chemokines like IL-8. In addition, they reduce the expression of inflammatory cell adhesion molecules and inhibit gene transcription of nitric oxide synthase, phospholipase A2, cyclooxygenase-2...
92
01:20The JAK-STAT Signaling Pathway
8.6K
Several cytokine receptors have tightly bound Janus kinase or JAK proteins attached at their cytosolic tail. Small signaling molecules such as cytokines, growth hormones, or prolactins bind to the cytokine receptors and initiate their dimerization. The dimerization brings the cytosolic JAKs together that trans-phosphorylate and activates each other. The activated JAKs now phosphorylate cytosolic tails of the cytokine receptors, which serve as binding sites for adaptor proteins such as SH2...
8.6K